Twitter Thread by BharatBiotech

BharatBiotech
@BharatBiotech

COVAXIN® Proven SAFE in India's Largest Efficacy Trial. Final Phase-3 Pre-Print Data Published on https://t.co/JJh9n3aB6V

ANNOUNCEMENT

RESULTS FROM FINAL ANALYSIS PHASE-3 STUDY:

COVAXIN® WITH UNPARALLELED SAFETY



LARGEST EFFICACY TRIAL IN INDIA
Across 25 trial sites; 18-98 years of age



Against asymptomatic COVID-19 transmission



Against mild, moderate and severe COVID-19 disease



Against B.1.617.2 Delta Variant



Against severe COVID-19 disease reducing hospitalizations



WELL TOLERATED with minimal adverse events post-immunization

PREPRINT VERSION AVAILABLE ON medRxiv

25 YEARS OF INNOVATION

BHARAT BIOTECH

10 PUBLICATIONS

DATA TRANSPARENCY

Lead Innovation